REPL Stock Analysis: Replimune | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 1.231m USD | 12M Return: 161.8% | US76029N1063 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 25.1M
Qual. Beats: 0
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 8.1 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Replimune Group, Inc. is a clinical-stage biotechnology company developing and commercializing oncolytic immunotherapies designed to activate the immune system against cancer, with operations based in the United States and the United Kingdom. Its lead product candidate, RP1, is a selectively replicating version of HSV-1 engineered to express GALV-GP R(-) and human GM-CSF, being studied across a range of solid tumors. The company is also advancing RP2, which expresses an anti-CTLA-4 antibody-like protein intended to block immune response inhibition. Founded in 2015 and headquartered in Woburn, Massachusetts, Replimune listed on NASDAQ in 2018.
As a clinical-stage biotech, Replimune does not yet generate commercial product revenue and depends on R&D progress, clinical trial outcomes, and capital markets funding to advance its pipeline. Oncolytic immunotherapy is a therapeutic class that uses genetically modified viruses to selectively infect and destroy tumor cells while stimulating a broader anti-cancer immune response.
- RP1 CERPASS Phase 3 melanoma data readout expected
- FDA regulatory pathway and approval timeline for RP1
- Cash runway and capital allocation amid quarterly operating burn
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -1.04 > 0.02 and ΔFCF/TA -50.90 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -1.11 > 3% & CFO -279.1m > Net Income -297.0m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 5.23 > 1.5 & < 3 |
| Outstanding Shares: last quarter (96.9m) vs 12m ago 5.84% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 0.31%; Δ -0.31% > 0%) |
| Interest Coverage Ratio: -30.82 > 6 (EBIT TTM -291.7m / Interest Expense TTM 9.46m) |
| A: 0.64 (Total Current Assets 200.8m - Total Current Liabilities 38.4m) / Total Assets 252.4m |
| B: -5.28 (Retained Earnings -1.33b / Total Assets 252.4m) |
| C: -0.81 (EBIT TTM -291.7m / Avg Total Assets 361.0m) |
| D: 0.72 (Book Value of Equity 105.6m / Total Liabilities 146.8m) |
| Altman-Z'' = -17.66 = D |
As of October 15, 2026, the stock is trading at USD 11.39 with a total of 1,861,706 shares traded. Over the past week, the price has changed by -13.71%, over one month by -13.12%, over three months by +15.40% and over the past year by +161.84%.
Current recommended Stop Loss: 10.60 (which is 6.9% or 1 ATR below the current price).
Replimune has received a consensus analysts rating of 4.25. Therefore, it is recommended to buy REPL.
- StrongBuy: 5
- Buy: 2
- Hold: 0
- Sell: 0
- StrongSell: 1
| Analysts Target Price | 19.5 | 71.2% |
P/B = 11.5584
Revenue TTM = 0.0 USD
EBIT TTM = -291.7m USD
EBITDA TTM = -287.2m USD
Long Term Debt = 84.1m USD (from longTermDebt, last quarter)
Short Term Debt = 4.04m USD (from shortTermDebt, last quarter)
Debt = 139.8m USD (from shortLongTermDebtTotal, last quarter) + Leases 27.9m
Net Debt = -55.5m USD (calculated: Debt 139.8m - CCE 195.3m)
Enterprise Value = 1.18b USD (1.23b + Debt 139.8m - CCE 195.3m)
Interest Coverage Ratio = -30.82 (Ebit TTM -291.7m / Interest Expense TTM 9.46m)
EV/FCF = -4.47x (Enterprise Value 1.18b / FCF TTM -262.9m)
FCF Yield = -22.36% (FCF TTM -262.9m / Enterprise Value 1.18b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = 4.66 (Enterprise Value 1.18b / Total Assets 252.4m)
Interest Expense / Debt = 6.77% (Interest Expense 9.46m / Debt 139.8m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -230.4m (EBIT -291.7m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 4.71 (Total Current Assets 200.8m / Total Current Liabilities 42.7m)
Debt / Equity = 1.32 (Debt 139.8m / totalStockholderEquity, last quarter 105.6m)
Debt / EBITDA = 0.19 (negative EBITDA) (Net Debt -55.5m / EBITDA -287.2m)
Debt / FCF = 0.21 (negative FCF - burning cash) (Net Debt -55.5m / FCF TTM -262.9m)
Total Stockholder Equity = 186.4m (last 4 quarters mean from totalStockholderEquity)
RoA = -82.28% (Net Income -297.0m / Total Assets 252.4m)
RoE = -159.3% (Net Income TTM -297.0m / Total Stockholder Equity 186.4m)
RoCE = -107.8% (out of range, set to none) (EBIT -291.7m / Capital Employed (Equity 186.4m + L.T.Debt 84.1m))
RoIC = -105.7% (out of range, set to none) (NOPAT -230.4m / Invested Capital 218.1m)
WACC = 15.60% (E(1.23b)/V(1.37b) * Re(16.76%) + D(139.8m)/V(1.37b) * Rd(6.77%) * (1-Tc(0.21)))
Discount Rate = 16.76% (= CAPM, Blume Beta Adj.) -> capped to 13.17%
Shares (quarterly) Correlation: 93.54 | Cagr: 22.45%
[DCF] Fair Price = unknown (Cash Flow -262.9m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.0 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: 0.0 | # QB: 0
EPS current Quarter (2026-09-30): EPS=-0.79 | Chg30d=+5.40% | Revisions=+0% | Analysts=2
EPS next Quarter (2026-12-31): EPS=-0.76 | Chg30d=+3.80% | Revisions=+0% | Analysts=2
EPS current Year (2027-03-31): EPS=-3.01 | Chg30d=-1.01% | Revisions=+0% | GrowthEPS=+11.1% | GrowthRev=+0.0%
EPS next Year (2028-03-31): EPS=-1.82 | Chg30d=+10.76% | Revisions=-25% | GrowthEPS=+39.5% | GrowthRev=+497.8%
[Analyst] Revisions Ratio: -17% (up=1, down=2)